FIELD: medicine.
SUBSTANCE: group of inventions relates to treatment of diseases caused by abnormal cell growth. Agent inducing death of cancer cells contains a drug which inhibits GST-π, and a therapeutic agent which inhibits homeostasis-associated protein selected from a group consisting of a cell cycle regulating protein, - ATM, CDC25A, p21, PRKDC, RBBP8, SKP2, MCM10, RNPC1, CCNL1, CENPH, BRSK1, MCM8, CCNB3, MCMDC1 and MYLK, protein associated with suppression of apoptosis, - AATF, ALOX12, ANXA1, ANXA4, API5, ATF5, AVEN, AZU1, BAG1, BCL2L1, BFAR, CFLAR, IL2, MALT1, MCL1, MKL1, MPO, MTL5, MYBL2 and MYO18A, and protein associated with PI3K signaling pathway, - MTOR, IRAK1, IRS1, MYD88, NFKB1, PIK3CG, RAC1, AKT3, EIF4B, EIF4E, ILK, MTCP1, PIK3CA and SRF. Also disclosed are an agent inhibiting growth of cancer cells, a pharmaceutical composition for treating a disease caused by abnormal cell growth, a combination for inducing cancer cell death, a combination for inhibiting growth of cancer cells, a method of treating a disease caused by abnormal growth of cells.
EFFECT: group of inventions provides effective treatment of cancer diseases.
13 cl, 15 dwg, 5 ex
